Michael Ross
Net worth: 1 462 $ as of 2026-08-30
Net worth: 1 462 $ as of 2026-08-30
Michael A. Ross is Chairman at Euclid Vision Corp.
since 2015.
Dr. Ross is Independent Director at 20 since 2016.
Dr. Ross is Board Member at LarreaRX, Inc. Dr. Ross is Operating Partner at Havencrest Capital Management LLC since 2020.
Dr. Ross is Professor at The George Washington University Medical Center since 1979.
Formerly, Dr. Ross was President and Chief Executive Officer at Euclid Vision Corp.
Dr. Ross was Chief Executive Officer at E-P Therapeutics, Inc. from 2010 to 2012.
Dr. Ross was President at CPL, Inc. from 2007 to 2009.
Dr. Ross completed undergraduate studies at Dickinson College in 1971.
Dr. Ross earned a doctorate from George Washington University School of Medicine & Health in 1975.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
20/20 BIOLABS, INC. 0.02% | 2026-06-21 | 2,373 ( 0.02% ) | 1 462 $ | 2026-08-30 |
| Companies | Position | Start |
|---|---|---|
| 20/20 BIOLABS, INC. | Director/Board Member | 2016-06-30 |
Euclid Vision Corp.
Euclid Vision Corp. Medical SpecialtiesHealth Technology Manufactures ophthalmic diagnostic equipment & contact lenses and provides eye care services | Chairman | 2015-02-09 |
Havencrest Capital Management LLC
Havencrest Capital Management LLC Investment ManagersFinance Havencrest Capital invests in lower-middle market companies located in the United States with an EBITDA of USD 3 - 15 million and enterprise value of USD 25 - 250 million. The firm focuses on a broad range of sectors and industries. It participates in add on acquisitions, buyouts, recapitalization and growth stage capital transactions. It acquires controlling and non controlling stakes. | Private Equity Investor | 2020-03-31 |
LarreaRX, Inc.
LarreaRX, Inc. Pharmaceuticals: MajorHealth Technology Produces and distributes dietary supplements, cold sore lotions, and penetrating sprays | Director/Board Member | - |
The George Washington University Medical Center | Corporate Officer/Principal | 1978-12-31 |
| Companies | Position | End |
|---|---|---|
E-P Therapeutics, Inc.
E-P Therapeutics, Inc. E-P Therapeutics, Inc. implements standard privacy measures including recaptcha protection and cookie usage to enhance user experience and analyze traffic. The private company is based in Ridgefield, CT. | Chief Executive Officer | 2011-12-31 |
CPL, Inc.
CPL, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical ingredients | President | 2009-09-30 |
Euclid Vision Corp.
Euclid Vision Corp. Medical SpecialtiesHealth Technology Manufactures ophthalmic diagnostic equipment & contact lenses and provides eye care services | President | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 9 |
|---|---|
20/20 Biolabs, Inc.
20/20 Biolabs, Inc. Medical/Nursing ServicesHealth Services Develops and commercializes AI based laboratory-based blood tests | Health Services |
Euclid Vision Corp.
Euclid Vision Corp. Medical SpecialtiesHealth Technology Manufactures ophthalmic diagnostic equipment & contact lenses and provides eye care services | Health Technology |
LarreaRX, Inc.
LarreaRX, Inc. Pharmaceuticals: MajorHealth Technology Produces and distributes dietary supplements, cold sore lotions, and penetrating sprays | Health Technology |
Dickinson College
Dickinson College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CPL, Inc.
CPL, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical ingredients | Health Technology |
E-P Therapeutics, Inc.
E-P Therapeutics, Inc. E-P Therapeutics, Inc. implements standard privacy measures including recaptcha protection and cookie usage to enhance user experience and analyze traffic. The private company is based in Ridgefield, CT. | |
The George Washington University Medical Center | |
Havencrest Capital Management LLC
Havencrest Capital Management LLC Investment ManagersFinance Havencrest Capital invests in lower-middle market companies located in the United States with an EBITDA of USD 3 - 15 million and enterprise value of USD 25 - 250 million. The firm focuses on a broad range of sectors and industries. It participates in add on acquisitions, buyouts, recapitalization and growth stage capital transactions. It acquires controlling and non controlling stakes. | Finance |
George Washington University School of Medicine & Health
George Washington University School of Medicine & Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Select your edition
All financial news and data tailored to specific country editions